• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

软骨发育不全中编码成纤维细胞生长因子受体-3的基因突变。

Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.

作者信息

Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet J M, Maroteaux P, Le Merrer M, Munnich A

机构信息

Service de Génétique, INSERM U. 393, CNRS ER 88, Institut Necker, Hôpital des Enfants Malades, Paris, France.

出版信息

Nature. 1994 Sep 15;371(6494):252-4. doi: 10.1038/371252a0.

DOI:10.1038/371252a0
PMID:8078586
Abstract

Achondroplasia, the most common cause of chondrodysplasia in man (1 in 15,000 live births), is a condition of unknown origin characterized by short-limbed dwarfism and macrocephaly. More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals, suggesting that de novo mutations are of paternal origin. Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (10%). In contrast, homozygous achondroplasia is usually lethal in the neonatal period and affects 25% of the offspring of matings between heterozygous achondroplasia parents. The gene responsible for achondroplasia has been mapped to chromosome 4p16.3 (refs 7, 8); the genetic interval encompassing the disease gene contains a member of the fibroblast-growth-factor receptor (FGFR3) family which is expressed in articular chondrocytes. Here we report the finding of recurrent missense mutations in a CpG doublet of the transmembrane domain of the FGFR3 protein (glycine substituted with arginine at residue 380, G380R) in 17 sporadic cases and 6 unrelated familial forms of achondroplasia. We show that the mutant genotype segregates with the disease in these families. Thus it appears that recurrent mutations of a single amino acid in the transmembrane domain of the FGFR3 protein account for all cases (23/23) of achondroplasia in our series.

摘要

软骨发育不全是人类软骨发育异常最常见的原因(每15000例活产中有1例),是一种病因不明的疾病,其特征为短肢侏儒症和巨头畸形。超过90%的病例为散发性,且受累个体受孕时父亲年龄增加,提示新发突变源自父亲。受累个体可生育,软骨发育不全作为一种完全显性的常染色体显性性状遗传,导致该病出现罕见的家族形式(10%)。相比之下,纯合子软骨发育不全通常在新生儿期致死,且在杂合子软骨发育不全父母的后代中,有25%会受影响。导致软骨发育不全的基因已被定位于染色体4p16.3(参考文献7、8);包含该疾病基因的遗传区间含有成纤维细胞生长因子受体(FGFR3)家族的一个成员,该成员在关节软骨细胞中表达。在此,我们报告在17例散发性病例和6例无亲缘关系的软骨发育不全家族病例中,发现FGFR3蛋白跨膜结构域的一个CpG双联体中有反复出现的错义突变(第380位氨基酸残基处甘氨酸被精氨酸取代,G380R)。我们表明,在这些家族中,突变基因型与疾病共分离。因此,在我们的研究系列中,FGFR3蛋白跨膜结构域中单个氨基酸的反复突变似乎可解释所有软骨发育不全病例(23/23)。

相似文献

1
Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.软骨发育不全中编码成纤维细胞生长因子受体-3的基因突变。
Nature. 1994 Sep 15;371(6494):252-4. doi: 10.1038/371252a0.
2
Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia.软骨发育不全中纤维母细胞生长因子受体-3基因的突变
Horm Res. 1996;45(1-2):108-10. doi: 10.1159/000184768.
3
A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.常见的成纤维细胞生长因子受体3(FGFR3)基因突变存在于软骨发育不全中,但不存在于软骨发育低下中。
Am J Med Genet. 1995 Jan 2;55(1):127-33. doi: 10.1002/ajmg.1320550132.
4
Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.导致软骨发育不全和致死性发育异常的突变对成纤维细胞生长因子受体3的分级激活。
Nat Genet. 1996 Jun;13(2):233-7. doi: 10.1038/ng0696-233.
5
A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.成纤维细胞生长因子受体3酪氨酸激酶结构域的复发性突变导致软骨发育不全。
Nat Genet. 1995 Jul;10(3):357-9. doi: 10.1038/ng0795-357.
6
Clinical and molecular characteristics of Thai patients with achondroplasia.泰国软骨发育不全患者的临床和分子特征
Southeast Asian J Trop Med Public Health. 2001 Jun;32(2):429-33.
7
Achondroplasia in Turkey is defined by recurrent G380R mutation of the FGFR3 gene.在土耳其,软骨发育不全由FGFR3基因反复出现的G380R突变所定义。
Turk J Pediatr. 2003 Apr-Jun;45(2):99-101.
8
A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online.软骨发育不全中纤维母细胞生长因子受体3的一种新型错义突变Ile538Val。简短突变报道第122号。在线版。
Hum Mutat. 1998;11(4):333. doi: 10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU18>3.0.CO;2-G.
9
[Gly380Arg and Asn540Lys mutations of fibroblast growth factor receptor 3 in achondroplasia and hypochndroplasia in the Spanish population].[西班牙人群中软骨发育不全和低软骨发育不全患者成纤维细胞生长因子受体3的Gly380Arg和Asn540Lys突变]
Med Clin (Barc). 1999 Mar 6;112(8):290-3.
10
[Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].[智利特发性身材矮小、软骨发育不全和软骨发育不全患者成纤维细胞生长因子受体3基因(FGFR3)的突变]
Rev Med Chil. 2003 Dec;131(12):1405-10.

引用本文的文献

1
Novel estrogen-related gene variants identified by whole-exome sequencing in pregnancy-associated intrahepatic cholestasis.通过全外显子组测序在妊娠合并肝内胆汁淤积症中鉴定出的新型雌激素相关基因变异体。
Front Genet. 2025 Aug 26;16:1626890. doi: 10.3389/fgene.2025.1626890. eCollection 2025.
2
Assessing the clinical relevance of MRI findings in adult achondroplasia patients with lumbar spinal stenosis.评估成年软骨发育不全性腰椎管狭窄症患者MRI检查结果的临床相关性。
Brain Spine. 2025 Jul 28;5:104374. doi: 10.1016/j.bas.2025.104374. eCollection 2025.
3
The genetic basis of human height.
人类身高的遗传基础。
Nat Rev Genet. 2025 Apr 7. doi: 10.1038/s41576-025-00834-1.
4
Real-world Outcome of Vosoritide Treatment in Children With Achondroplasia: A 12-month Retrospective Observational Study.维索利肽治疗软骨发育不全儿童的真实世界结局:一项为期12个月的回顾性观察研究。
J Endocr Soc. 2025 Mar 8;9(5):bvaf041. doi: 10.1210/jendso/bvaf041. eCollection 2025 Mar 24.
5
Challenges of engineering a functional growth plate .构建功能性生长板的挑战。
Front Bioeng Biotechnol. 2025 Mar 4;13:1550713. doi: 10.3389/fbioe.2025.1550713. eCollection 2025.
6
Current understanding and perspectives on growth and long-acting GH therapy in Japan.日本对生长及长效生长激素治疗的当前认识与观点
Clin Pediatr Endocrinol. 2025 Jan;34(1):1-12. doi: 10.1297/cpe.2024-0058. Epub 2024 Oct 26.
7
International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia.关于在软骨发育不全个体中实施和监测维索利肽治疗的国际共识指南。
Nat Rev Endocrinol. 2025 May;21(5):314-324. doi: 10.1038/s41574-024-01074-9. Epub 2025 Jan 6.
8
Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and Cancer.估计六种非肿瘤和癌症相互排斥实体中的多基因疾病数量。
Int J Mol Sci. 2024 Nov 7;25(22):11968. doi: 10.3390/ijms252211968.
9
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors.FGFR基因改变实体瘤诊断与治疗专家共识
Glob Med Genet. 2024 Sep 16;11(4):330-343. doi: 10.1055/s-0044-1790230. eCollection 2024 Dec.
10
Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia.氯苯甲嗪和生长激素可改善软骨发育不全实验模型中的骨长度和质量。
J Bone Miner Metab. 2025 Mar;43(2):74-85. doi: 10.1007/s00774-024-01563-x. Epub 2024 Nov 8.